Marksans Pharma Ltd Completes Acquisition of 100% Stake in Netherlands-Based QliniQ B.V.
Marksans Pharma Limited has completed the acquisition of 100% share capital of QliniQ B.V., a company based in the Netherlands. The completion of this transaction marks a significant step for the pharmaceutical firm, enhancing its international footprint following prior communications regarding the deal structure.MARKSANS Stock Price Movement
As of 3:23 PM, shares of Marksans Pharma Limited are slipping by 0.84% in live trading, currently priced at ₹247.66 after shedding ₹2.10 per share. The stock has seen a robust intraday volume of 1,675,092 shares.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.